Skip to main content
Premium Trial:

Request an Annual Quote

Michael Vicari

OncoCyte has appointed Michael Vicari to a newly created position of vice president of sales, in which he will report directly to president and CEO William Annett. In his new role, Vicari will be responsible for the development and successful implementation of domestic and international sales strategies for OncoCyte, with an initial focus on the expected fourth quarter US launch of the firm's liquid biopsy lung cancer test DetermaVu.

Vicari comes with 35 years of successful sales and marketing leadership within the healthcare industry, including the launch of several important diagnostic products, OncoCyte said. He previously worked with Eurofins Scientific as VP of sales & marketing for the company's clinical diagnostics business. Prior to Eurofins, he was VP of sales for Sequenom, for Monogram Biosciences, and served in senior commercial leadership roles at Genentech, Corixa Oncology, and MedImmune.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more